The present study aims to image the 18-kDa translocator protein (TSPO; formerly known as the peripheral benzodiazepine receptor) in a preclinical human breast cancer (BC) xenograft mouse model with positron-emission tomography (PET). An automated radiosynthesis of [18F]-N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide ([18F]FEPPA) was validated for human use using a commercial synthesis module and resulted in a high radiochemical yield (30%±8%, uncorrected; n=54) and specific activity (6±4 Ci/μmol). Tumor uptake of [18F]FEPPA in mice bearing subcutaneous MDA-MB-231 BC xenografts was evaluated by PET-computed tomography imaging and ex vivo biodistribution studies. Although the tumor was successfully visualized, ex vivo biodistribution studies revealed low tumor uptake (0.7%ID/g), with the majority of radioactivity distributed in the spleen, muscle, and heart despite high TSPO expression in this cell line. Our laboratory routinely prepares [18F]FEPPA for human-imaging studies in the central nervous system, and we envision that radiopharmaceuticals that target the TSPO have the potential for imaging macrophages in the tumor microenvironment.
Get full access to this article
View all access options for this article.
References
1.
VermaA, FacchinaSL, HirschDJet al.Photodynamic tumor therapy: Mitochondrial benzodiazepine receptors as a therapeutic target. Mol Med, 1998; 4:40.
2.
SchlichterR, RybalchenkoV, PoisbeauPet al.Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology, 2000; 39:1523.
BenavidesJ, QuarteronetD, ImbaultFet al.Labelling of “peripheral-type” benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: Kinetic studies and autoradiographic localization. J Neurochem, 1983; 41:1744.
5.
TallmanJF, ThomasJW, GallagerDW. GABAergic modulation of benzodiazepine binding site sensitivity. Nature, 1978; 274:383.
6.
AnholtRR, MurphyKM, MackGEet al.Peripheral-type benzodiazepine receptors in the central nervous system: Localization to olfactory nerves. J Neurosci, 1984; 4:593.
7.
BeardCM, WaringSC, O'BrienPCet al.Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: A case-control study in Rochester, Minnesota, 1980–1984. Mayo Clin Proc, 1998; 73:951.
8.
CymermanU, PazosA, PalaciousJM. Evidence for species differences in “peripheral” benzodiazepine receptors: An autoradiographic study. Neurosci Lett, 1986; 66:153.
9.
MaaserK, SutterAP, ScherüblH. The peripheral benzodiazepine receptor: A target for innovative diagnostic and therapeutic approaches in gastrointestinal oncology. Cancer Ther, 2004; 2:345.
10.
HardwickM, FertikhD, CultyMet al.Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res, 1999; 4:831.
11.
BeinlichA, StrohmeierR, KaufmannMet al.Relation of cell proliferation to expression of peripheral benzodiazepine receptors in human breast cancer cell lines. Biochem Pharmacol, 2000; 60:397.
12.
HardwickM, RoneJ, HanZQet al.Peripheral-type benzodiazepine receptor levels correlate with the ability of human breast cancer MDA-MB-231 cell line to grow in SCID mice. Int J Cancer, 2001; 94:322.
13.
HanZQ, SlackRS, LiWet al.Expression of peripheral benzodiazepine receptor (PBR) in human tumors: Relationship to breast, colorectal, and prostate tumor progression. J Recept Signal Transduct Res, 2003; 23:225.
14.
ZhengJ, BoisgardR, Siquier-PernetKet al.Differential expression of the 18 kDa translocator protein (TSPO) by neoplastic and inflammatory cells in mouse tumors of breast cancer. Mol Pharmacol, 2011; 8:823.
15.
HunakovaL, BodoJ, ChovancovaJet al.Expression of new prognostic markers, peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines. Neoplasma, 2007; 54:541.
16.
American Cancer Society. Cancer Facts and Figures. Atlanta: American Cancer Society, 2009.
17.
LaouiD, MovahediK, OvermeireEVet al.Tumor-associated macrophages in breast cancer: Distinct subsets, distinct functions. Int J Dev Biol, 2011; 55:861.
18.
PappataS, LevasseurM, GunnRNet al.Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology, 2000; 55:1052.
19.
BanatiRB, GoerresGW, MyersRet al.[11C]-(R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology, 1999; 53:2199.
20.
CagninA, MyersR, GunnRNet al.[11C]-(R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain, 2001; 124:2014.
21.
TurnerMR, CagninA, TurkheimerFEet al.Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C]-(R)-PK11195 positron emission tomography study. Neurobiol Dis, 2004; 15:601.
22.
GerhardA, BanatiRB, GoerresGBet al.[11C]-(R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology, 2003; 61:686.
23.
PappataS, CornuP, SamsonYet al.PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: A case report. J Nucl Med, 1991; 32:1608.
24.
SauvageauA, DesjardinsP, LozevaVet al.Increased expression of “peripheral-type” benzodiazepine receptors in human temporal lobe epilepsy: Implications for PET imaging of hippocampal sclerosis. Metab Brain Dis, 2002; 17:3.
25.
ChauveauF, BoutinH, Van CampNet al.Nuclear imaging of neuroinflammation: A comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging, 2008; 35:2304.
26.
DolléF, LuusC, ReynoldsAet al.Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography. Curr Med Chem, 2009; 16:2899.
27.
LuusC, HananiR, ReynoldsAet al.The development of PET radioligands for imaging the translocator protein 18 kDa: What have we learned?J Labelled Compd Radiopharm, 2010; 53:501.
28.
QuonA, GambhirSS. FDG-PET and beyond: Molecular breast cancer imaging. J Clin Oncol, 2005; 23:1664.
29.
PantaleoMA, NanniniM, MaledduAet al.Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev, 2008; 34:103.
30.
WilsonAA, GarciaA, ParkesJet al.Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol, 2008; 35:305.
31.
van OostenEM, WilsonAA, StephensonKAet al.An improved radiosynthesis of the muscarinic M2 radiopharmaceutical, [18F]FP-TZTP. Appl Radiat Isot, 2009; 67:611.
32.
VinesDC, GreenDE, KudoGet al.Evaluation of mouse tail-vein injections both qualitatively and quantitatively on small-animal PET tail scans. J Nucl Med Technol, 2011; 39:264.
33.
RusjanPM, WilsonAA, BloomfieldPMet al.Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab, 2011; 31:1807.
34.
WyattSK, ManningHC, BaiMet al.Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer. Mol Imaging Biol, 2010; 12:349.
35.
McLartyK, FasihA, ScollardDAet al.18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice. J Nucl Med, 2009; 50:1848.
36.
BrownAK, FujimuraY, LiowJ-Set al.Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: A PET radioligand to image inflammation. J Nucl Med, 2007; 48:2072.
37.
ChingASC, KuhnastB, DamontAet al.Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging, 2012; 3:111.
38.
OwenDR, GunnRN, RabinerEAet al.Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med, 2011; 52:24.
39.
ScarfAM, KassiouM. The translocator protein. J Nucl Med, 2011; 52:677.
40.
OwenDR, YeoAJ, GunnRNet al.An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab, 2012; 32:1.
41.
JunckL, OlsonJM, CiliaxBJet al.PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol, 1989; 26:752.
42.
BuckJR, McKinleyET, HightMRet al.Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline. J Nucl Med, 2011; 52:107.
43.
TangD, HightMR, McKinleyETet al.Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy) phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide. J Nucl Med, 2012; 53:287.
44.
ChenY, SajjadM, WangYet al.TSPO 18 kDa (PBR) targeted photosensitizers for cancer imaging (PET) and PDT. ACS Med Chem Lett, 2011; 2:136.
